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Abstract
Background: Cardiorenal anemia syndrome (CRAS) is an evolving global epidemic associated with increased
morbimortality and cost of care. The management of patients with CRAS remains a challenging undertaking
worldwide and the lack of evidence-based clinical guidelines adds to the challenge. We aimed to explore the
prevalence and survival rates of heart failure patients with CRAS in Tanzania.
Methods: We screened 789 patients and consecutively recruited 463 who met the inclusion criteria. Each
participant underwent an interview, physical examination, anthropometric measurements, anemia, renal
functions and echocardiographic assessment. All participants were followed until death or for up-to 180 days,
whichever came first. Bivariate comparison and subsequent Cox proportional-hazards regression model were
used to compare the CRAS and non-CRAS groups with respect to the primary end point.
Results: The mean age of participants was 46.4 ± 18.9 years, and 56.5% were women. Overall, 51.9% of participants
had renal insufficiency, 72.8% were anemic and 44.4% had CRAS. During a mean follow-up of 103 ± 75 days, 57.8%
of participants died. Patients with CRAS displayed a higher mortality rate (73.5%) compared to those free of CRAS (45.
8%), (p < 0.001). During multivariate analysis in a cox regression model of 21 potential predictors of mortality; renal
dysfunction (HR 1.9; 95% CI 1.0–3.5; p = 0.03), severe anemia (HR 1.8; 95% CI 1.0–3.1; p = 0.04), hyponatremia (HR 2.2;
95% CI 1.3–3.7; p = 0.004) and rehospitalization (HR 4.3; 95% CI 2.2–8.4; p < 0.001) proved to be the strongest factors.
Conclusion: Cardiorenal anemia syndrome is considerably prevalent and is associated with an increase in mortality
amongst patients with heart failure. In view of this, timely, aggressive and collaborative measures to improve renal
functions and/or correct anemia are crucial in the management of CRAS patients. Furthermore, these findings call for
guideline committees to revise and/or develop evidence-based recommendations for management of patients with CRAS.
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Background
Comorbid heart failure, renal failure and anemia
commonly referred to as cardiorenal anemia syndrome
(CRAS) is an evolving epidemic encountered by health-
care professionals worldwide. The interactive links
between the CRAS triad are complex and multi-factorial
with high potential for increased morbidity, mortality,
complexity and cost of care. Studies have reported CRAS
prevalence ranging from 19 to 62% and mortality rates of
up-to 51% amongst heart failure patients [1–8].
The management of patients with CRAS remains a chal-
lenging undertaking largely due to the complexity and het-
erogeneity of this syndrome. Furthermore, the present
clinical guidelines lack evidence-based recommendations
for managing patients with CRAS. Despite the evidence of
increasing hospitalizations due to heart failure and renal
dysfunction, CRAS has not been thoroughly explored in
Tanzania. To investigate on this subject, we performed a
prospective cohort study to determine the prevalence and
survival rates of heart failure patients with CRAS.
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Methods
Recruitment process and definition of terms
From March through October 2014, we screened for and
consecutively enrolled patients with clinical diagnosis of
heart failure who were admitted to Muhimbili National
Hospital and the Jakaya Kikwete Cardiac Institute in Dar es
Salaam, Tanzania. Demographic, clinical, laboratory, and
echocardiographic data were gathered during the hospital
admission of enrollment. We employed the following pro-
spective selection criteria. Patients were included if they had
symptoms of heart failure as per the Framingham criteria
and later patients underwent a 2-dimensional echocardiog-
raphy for diagnosis confirmation. We used an ejection frac-
tion (EF) of below 45% to denote a systolic dysfunction.
Renal dysfunction and anemia were diagnosed using the
serum creatinine (sCr) and hemoglobin (Hb) measurements
respectively. We estimated the renal functions with the
Modification of Diet in Renal Disease (MDRD) equation,
where estimated glomerular filtration rate (eGFR) (mL/min/
1.73 m2) = 186.3 × sCr - 1.154 × age - 0.203 × 0.742 (if
female). No correction for race was necessary as all partici-
pants were of African descent. Renal dysfunction was de-
fined by an eGFR value of <60 mL/min/1.73 m2. WHO
criteria for anemia i.e. Hb concentration of <13.0 g/dL for
males and <12.0 g/dL for females was used to diagnose
anemia. Participants were categorized as having CRAS if
they had both renal dysfunction and anemia.
Follow-up and study outcomes
Follow-up continued through April 2015, data was censored
at the time of death or after the completion of the 180-day
follow-up period, whichever occurred first. Follow-up was
conducted through weekly phone calls and a participant was
deemed lost to follow-up when all of the 3 phone numbers
given during enrollment were not reachable in 3 different
occasion 7-days apart, with at least 3 attempts on each occa-
sion. The primary outcome measure was the all-cause mor-
tality within 180 days after enrollment.
Statistical analysis
STATA v11.0 software was utilized in all statistical analyses.
We compared categorical variables using the Pearson Chi
square tests or Fisher’s exact tests; Student’s T-test was used
in comparison of continuous variables. Bivariate compari-
son and subsequent Cox proportional-hazards regression
model were used to compare the CRAS and non-CRAS
groups with respect to the primary end point. Statistically
significant variables maintained in the regression final
model underwent stepwise and backward selection proce-
dures. The multivariate models were fitted with baseline co-
variates associated with mortality by bivariate analysis at
the <0.05 significance level. Wald Chi-Square tests was used
to assess for the interaction terms, with p < 0.1 considered
significant. We did not include patients with missing data
or those lost to follow-up in the regression analyses. Differ-
ences in survival between the two groups were compared
using the log-rank test. Hazard ratios with 95% confidence
intervals and p-values are reported. All tests were 2-sided,
and statistical significance was defined by p < 0.05.
Results
Study population
Figure 1 shows the study profile (enrollment, follow-up
and survival). During the study period, 463 of the 789
screened patients met the inclusion criteria and were re-
cruited into this study. The baseline demographic char-
acteristics were similar amongst study participants
regardless of their CRAS status; however, their baseline
clinical and laboratory characteristics displayed a differ-
ent pattern, Table 1. The mean age of participants was
Fig. 1 Study Profile
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Table 1 Baseline Demographic & Clinical Characteristics of the Study Population
Characteristic All Patients (n = 455) CRAS (n = 202) Non-CRAS (n = 253) p-Value
Demographics
- Age, mean (SD), years 46.4 (18.9) 48.1 (17.8) 45.0 (19.7)
- Age groups 0.09
< 30 112 (24.6) 42 (20.8) 70 (27.7) 0.09
30–50 140 (30.8) 65 (32.2) 75 (29.6) 0.56
> 50 203 (44.6) 95 (47.0) 108 (42.7) 0.35
- Female sex, no (%) 257 (56.5) 124 (61.4) 133 (52.6) 0.06
- Primary education (%) 319 (70.1) 136 (67.3) 183 (72.3) 0.25
- Self-employment (%) 226 (49.7) 99 (49.0) 127 (50.2) 0.80
- Urban residence (%) 303 (66.6) 132 (65.4) 171 (67.6) 0.61
- Ever smoker (%) 49 (10.8) 22 (10.9) 27 (10.7) 0.95
- Health insurance (%) 97 (21.3) 41 (20.3) 56 (22.1) 0.64
Vital sign, mean (SD)
- Respiratory Rate, breaths/min 24.1 (6.5) 23.9 (6.5) 24.3 (6.5) 0.48
- Heart rate, beats/min 98.5 (22.2) 94.5 (21.0) 101.7 (22.7) <0.001
- Systolic BP, mmHg 132.4 (35.9) 144.7 (40.2) 122.5 (28.5) <0.001
- Diastolic BP, mmHg 82.3 (24.7) 87.2 (26.6) 78.4 (22.3) <0.001
- Oxygen saturation, % 96.3 (7.6) 96.5 (7.6) 96.2 (7.6) 0.64
- NYHA III&IV (%) 420 (92.3) 188 (93.1) 232 (91.7) 0.58
- BMI, kg/m2 25.1 (5.2) 25.6 (4.7) 24.8 (5.6) 0.13
Serum concentration, mean (SD)
- Hemoglobin, g/dL 10.3 (3.1) 8.3 (2.3) 9.9 (2.1)a <0.001
- Mean Cell Volume, fL 82.9 (9.0) 81.5 (8.4) 84.0 (9.4) <0.01
- Mean Cell Hemoglobin, pg/cell 26.6 (3.6) 25.9 (3.1) 27.1 (4.0) <0.001
- Creatinine, μmol/L 446.3 (679.1) 870.1 (838.2) 278.2 (224.0)b <0.001
- Total cholesterol, mg/dl 4.2 (2.2) 5.0 (2.4) 3.6 (1.8) <0.001
- LDL cholesterol, mg/dl 3.2 (2.0) 3.9 (2.1) 2.5 (1.7) <0.001
- HDL cholesterol, mg/dl 1.0 (0.4) 0.9 (0.5) 1.0 (0.4) 0.25
- Sodium, mmol/L 132.0 (8.3) 131.3 (8.8) 132.6 (7.9) 0.9
Hyponatremia (%) 232 (54.7) 112 (59.3) 120 (51.1) 0.09
- Potassium, mmol/L 4.4 (1.3) 4.9 (1.5) 4.1 (1.0) 0.9
Hypokalemia (%) 80 (18.4) 28 (14.5) 52 (21.6) 0.06
Hyperkalemia (%) 130 (30.0) 87 (45.1) 43 (17.8) <0.001
- Calcium, mmol/L 2.1 (0.3) 2.1 (0.3) 2.1 (0.2) 1
Hypocalcemia (%) 169 (48.8) 94 (54.3) 75 (43.4) 0.04
- Magnesium, mmol/L 0.9 (0.2) 0.9 (0.2) 0.8 (0.1) 1
Hypomagnesemia (%) 41 (16.1) 14 (11.0) 27 (21.1) 0.03
Comorbid conditions
- Hypertension (%) 246 (54.1) 143 (70.8) 103 (40.7) <0.001
- Diabetes (%) 67 (14.7) 42 (20.8) 25 (9.9) <0.01
- HIV (%) 31 (6.8) 18 (8.9) 13 (5.1) 0.11
Admission Duration, mean, days (SD) 13.9 (13.0) 14.4 (11.0) 13.5 (14.5) 0.42
a and b represents anemic (n = 129) and renal insufficiency (n = 34) subgroups amongst non-CRAS participants respectively
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46.4 ± 18.9 years, and 257 (56.5%) were women. Ninety
two point three percent (92.3%) of patients were in New
York Heart Association (NYHA) functional class III/IV
on admission. A total of 246 (54.1%) participants had a
history of hypertension, 67 (14.7%) had diabetes and 31
(6.8%) were HIV infected (Additional file 1).
Prevalence and associated factors for CRAS
Of the 455 participants with complete data, 236 (51.9%)
had renal insufficiency and 331 (72.8%) had anemia. We
found that 202 (44.4%) of our heart failure cohort had
the CRAS. Participants with CRAS displayed a higher
likelihood for both end-stage renal disease (ESRD)
(eGFR < 15) and the severe form of anemia (Hb < 8 g/
dL) compared to their non-CRAS counterparts with
renal dysfunction or anemia, (both p < 0.001). Comorbid
diabetes or hypertension was associated with higher
rates of CRAS compared to those free from either condi-
tion, (p < 0.01 & p < 0.001 respectively).
Overall, hypertensive heart diseases (40.9%) was the
leading cause of heart failure, followed by cardiomyopa-
thies (26%) and valvular heart diseases (23%). Of the
valvular etiology, 82.6% were attributable to rheumatic
heart disease. We observed that 114/236 (48.3%) of par-
ticipants with renal insufficiency were in ESRD and 14
(12.3%) of these were on dialysis. Normocytic normo-
chromic anemias constituted 180/331 (54.4%) of ane-
mias, while the microcytic hypochromic form was found
in 107/331 (32.3%) of anemic subjects.
Primary outcome
During a mean follow-up of 103 ± 75 days, 241/417
(57.8%) participants died, with 21.6% of these fatalities
occurring either at home or on the way to a health facil-
ity. Patients with CRAS had a significantly higher mor-
tality rate 133/181 (73.5%) compared to those free of
CRAS 108/236 (45.8%), (p < 0.001), Fig. 2. Mortality rate
was observed to increase with worsening of heart failure
i.e. 33.3%, 54.2%, and 63.2% in NYHA class II, III, and
IV respectively. Presence of anemia and/or renal insuffi-
ciency was observed to independently and synergistically
increase the mortality rate, Table 2. During multivariate
analysis in a cox regression model of 21 potential associ-
ated factors for mortality; renal dysfunction (HR 1.9;
95% CI 1.0–3.5; p = 0.03), severe anemia (HR 1.8; 95%
CI 1.0–3.1; p = 0.04), hyponatremia (HR 2.2; 95% CI
1.3–3.7; p = 0.004) and rehospitalization (HR 4.3; 95% CI
2.2–8.4; p < 0.001) proved to be the strongest factors.
Subgroup analysis
The superior rate of death observed in participants with
CRAS was consistent across all major subgroup analyses
we conducted, (Fig. 3). Overall, patients with CRAS
displayed a two times mortality rate compared to non-
CRAS participants, (HR 2.1, 95% CI 1.6–2.6, p < 0.001).
Discussion
The present study shows that CRAS is considerably
prevalent and is associated with increased mortality
among hospitalized patients with heart failure. These ob-
servations are in unison with the previously published
data [1–8]. Compared to participants without comorbid
renal dysfunction and anemia, patients with CRAS had a
2-fold mortality hazard. Contrary to previous studies, we
observed very high mortality rates within a short period
of follow-up. These findings were independent of
demographic confounders and established risk factors.
Over one fifth of the deceased participants died before
reaching a health facility. The authors believe this is so
because of the weak emergency systems, poor infrastruc-
ture and extreme poverty which hinder a timely access
to healthcare services in low and medium countries like
Tanzania.
The mean age of our heart failure cohort was 46 years.
This is a relatively young age compared to the mean of
>70 years reported in the western world [9–11]. Such
Fig. 2 Cox Proportional Hazard Model Survival Curve by CRAS
Table 2 Mortality Rates (%) by CRAS Triad Components at 30,
90 & 180 Days
30-day 90-day 180-day
HF 22.7 31.3 39.0
HF + Anemia 24.6 39.7 47.5
HF + CKI 33.3 50.0 55.9
HF + CKI + Anemia 41.4 62.4 73.5
Key: HF Heart Failure, CKI Chronic Kidney Insufficiency
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young onset of heart failure has been reported in a
number of developing nations and remain a major con-
cern. Hypertension continues to be the leading cause of
heart failure in resource limited settings. We observed
that hypertensive patients had a doubled risk of having
CRAS compared to their hypertension-free counterparts,
(RR = 2.1, 95% CI 1.6–2.6, p < 0.001).
Renal insufficiency was present in over a half of the
study participants. These findings are in consonance
with a number of previous studies [12, 13]. Anemia
prevalence and severity was found to increase with wors-
ening of renal functions. These findings are in keeping
with our current understanding of anemia’s potential in
causing renal insufficiency as well as worsening it. Only
12% of patients in ESRD were on dialysis, this is prob-
ably due to the remaining high cost of dialysis despite an
increasing number of service providers in this setting.
Almost three-quarters of patients in this present study
were anemic. The reported anemia rates among heart
failure patients have a wide range among studies and
our rate falls within [1]. This variability is partly attribut-
able to the use of inconsistent definitions of anemia (i.e.
Hb cut-off points) and/or different inclusion criteria for
age among studies. In this set-up however the anemia
prevalence is reportedly high even in the general popula-
tion almost certainly due to a significant burden of
malnutrition and infectious diseases. We therefore
hypothesize that a good number of heart failure patients
were primarily anemic even before the onset of heart
failure.
Our study has several strengths. First, our diagnosis of
heart failure though initially utilized a screening tool
(Framingham criteria), the diagnostic confirmation relied
on a 2-dimensional echocardiography. Enrolled patients
were admitted in a tertiary hospital with a national sta-
tus receiving cases from the whole country and thus our
findings are perhaps generalizable to Tanzania and simi-
lar resource limited settings. We reported the all-cause
mortality which is a relatively unbiased and the most
valid endpoint.
This study was observational with obvious limitations.
The absence of serial measurements of hemoglobin and
creatinine in this study implies that we missed new cases
and trends of progression of anemia and renal insuffi-
ciency that occurred during the follow-up period. More-
over, with a single creatinine measurement taken, we
were not in a position to qualify whether the renal insuf-
ficient participants were in acute or chronic phase.
Conclusion
The CRAS is considerably prevalent and is associated
with an increase of mortality amongst patients with
heart failure. Our results suggest that in patients with
heart failure; timely, aggressive and collaborative mea-
sures to improve renal functions and/or correct anemia
might improve survival of heart failure patients. Further-
more, these findings call for guideline committees to
revise and/or develop evidence-based recommendations
for management of patients with CRAS.
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